Merck Janumet Study Demonstrates Glucose Reductions In Two Measures
This article was originally published in The Pink Sheet Daily
Executive Summary
Data on the investigational type 2 diabetes drug is pivotal to Merck’s NDA submission for the sitagliptin/metformin combination.
You may also be interested in...
Merck Gains Positive Opinion For Januvia In EU
Firm expects final EU clearance in early April.
Merck Gains Positive Opinion For Januvia In EU
Firm expects final EU clearance in early April.
Galvus Review Delayed For Safety Analysis Of Primate Skin Data
FDA pushes the user fee for the DPP-4 inhibitor back until the end of February.